A prospective randomized controlled trial for postoperative adjuvant chemotherapy for pTanyN0M0 bladder urothelial carcinoma with lymphangiogenesis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900024860

Enrollment

Unknown

Registered

2019-07-31

Start date

2019-08-01

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder cancer

Interventions

1:GC regimen chemotherapy

2:Observation group

Eligibility

Sex/Gender

All

Age

20 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Aged 20-85 years; 2. ECOG score 0-1 points; 3. Patients with bladder urothelial carcinoma, undergoing radical cystectomy, pathological staging For pTanyN0M0; 4. Patients voluntarily signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Obvious cardiopulmonary dysfunction, serious diabetes and other chronic diseases; 2. Obvious chemotherapy contraindications; 3. Patients have a history of other organ malignancies; 4. Combined with tumors of other sites.

Design outcomes

Primary

Measure	Time frame
3-year Overall survival rate;	—

Countries

China

Contacts

Public ContactMa Baojie

The Second Hospital of Tianjin Medical University

scalpeltj@163.com+86 13920809892

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026